Shalby Limited (NSE:SHALBY)
India
· Delayed Price · Currency is INR 201.25
-0.53 (-0.26%)
May 22, 2025, 3:29 PM IST
Shalby Revenue
Shalby had revenue of 2.76B INR in the quarter ending December 31, 2024, with 27.58% growth. This brings the company's revenue in the last twelve months to 10.66B, up 20.01% year-over-year. In the fiscal year ending March 31, 2024, Shalby had annual revenue of 9.34B with 16.00% growth.
Revenue (ttm)
10.66B
Revenue Growth
+20.01%
P/S Ratio
2.03
Revenue / Employee
3.74M
Employees
2,853
Market Cap
21.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 9.34B | 1.29B | 16.00% |
| Mar 31, 2023 | 8.05B | 1.06B | 15.16% |
| Mar 31, 2022 | 6.99B | 2.68B | 62.21% |
| Mar 31, 2021 | 4.31B | -559.57M | -11.49% |
| Mar 31, 2020 | 4.87B | 245.93M | 5.32% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 271.45B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 235.11B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Shalby News
- 3 months ago - Q3 2025 Shalby Ltd Earnings Call Transcript - GuruFocus
- 3 months ago - Shalby shares drop 4% as EBITDA falls 20.1% YoY in Q3 - Business Upturn
- 4 months ago - Shalby shares jump 3% after FDA approval for Duraniom knee replacement device - Business Upturn
- 10 months ago - Monogram Technologies announces strategic collaboration with Shalby Limited - Seeking Alpha